⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950529 | 0.80 | — | — | |
| SCHEMBL6677669 | 0.79 | — | — | |
| SCHEMBL80383 | 0.78 | — | — | |
| SCHEMBL28521 | 0.78 | — | — | |
| SCHEMBL3420463 | 0.76 | — | — | |
| SCHEMBL186024 | 0.76 | — | — | |
| SCHEMBL1006386 | 0.72 | — | — | |
| SCHEMBL4951731 | 0.70 | — | — | |
| SCHEMBL775219 | 0.70 | — | — | |
| SCHEMBL4950749 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | claimed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | claimed |
| US-20230001395-A1 | Catalysts for Olefin Metathesis, Methods of Preparation, and Processes for the Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-01-05 | — | — | US | claimed |
| WO-2021072231-A1 | CATALYSTS FOR OLEFIN METATHESIS, METHODS OF PREPARATION, AND PROCESSES FOR THE USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2021-04-15 | — | — | WO | claimed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | claimed |
| US-20210094973-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | claimed |
| WO-2021058445-A1 | NEW HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | claimed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | claimed |
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | claimed |
| WO-2019180185-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | WO | claimed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | claimed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | claimed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| US-6828315-B1 | Anti- inflammatories, anti-allergics, bronchodilatators, anti-asthmatics, or TNF alpha inhibitors | WARNER-LAMBERT LLC | 2004-12-07 | — | — | US | claimed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2001072757-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000063211-A1 | HALOALKOXY IMIDAZONAPHTHYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-26 | — | — | WO | disclosed |
| US-4698093-A | POST, PRE EMERGENTS | MONSANTO COMPANY (US) | 1987-10-06 | — | — | US | disclosed |